KA/EN
Register
Medicines reference
Search
Search
Active substance

Tiletamine/Zolazepam

Favourites

Dissociative anaesthetic with a benzodiazepine. Registered in Georgia: 2 veterinary products. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Tiletamine/Zolazepam
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
5 mg/kg Dog, Cat Anaesthesia for Tests and Procedures Causing Little Pain
Loading
 Intravenous once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Zoletil 100 (50 mg/ml + 50 mg/ml) lyophilisate and solvent for solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
7.5 mg/kg Dog, Cat Anaesthesia for Minor Surgery or Short Anaesthesia; Anaesthesia for Orthopaedic Surgery
Loading
 Intravenous once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Zoletil 100 (50 mg/ml + 50 mg/ml) lyophilisate and solvent for solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
10 mg/kg Dog, Cat Anaesthesia for Painful Interventions; Anaesthesia for Tests and Procedures Causing Little Pain
Loading
 Intravenous / Intramuscular once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Zoletil 100 (50 mg/ml + 50 mg/ml) lyophilisate and solvent for solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
7–10 mg/kg Dog Anaesthesia for Tests and Procedures Causing Little Pain
Loading
 Intramuscular once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Zoletil 100 (50 mg/ml + 50 mg/ml) lyophilisate and solvent for solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
10–15 mg/kg Dog Anaesthesia for Minor Surgery or Short Anaesthesia
Loading
 Intramuscular once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Zoletil 100 (50 mg/ml + 50 mg/ml) lyophilisate and solvent for solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
15–25 mg/kg Dog Anaesthesia for Painful Interventions
Loading
 Intramuscular once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Zoletil 100 (50 mg/ml + 50 mg/ml) lyophilisate and solvent for solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
15 mg/kg Cat Anaesthesia for Orthopaedic Surgery
Loading
 Intramuscular once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Zoletil 100 (50 mg/ml + 50 mg/ml) lyophilisate and solvent for solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in animals hypersensitive to tiletamine, zolazepam or the excipients (benzyl alcohol, lactose).
  • Critical
    Do not use in animals with severe heart disease.
  • Critical
    Do not use in animals with severe respiratory disease.
  • Critical
    Do not use in animals with renal insufficiency.
  • Critical
    Do not use in animals with hepatic insufficiency.
  • Critical
    Do not use in severe hypertension.
  • Critical
    Do not use in pregnant bitches and queens or for caesarean section: it crosses the placenta and can cause fatal respiratory depression in newborns.
  • Critical
    Do not use tiletamine/zolazepam in dogs or cats with pancreatic disease.
    Sources: Zoletil 100 UK SPC · FDA
  • Warning
    Safety in lactation has not been established; use only after a benefit-risk assessment.
  • Caution
    Do not use in severe hypertension, head trauma or intracranial tumours, pancreatic insufficiency, for caesarean section, or in rabbits. Do not give chloramphenicol before or during the anaesthetic; acepromazine premedication deepens cardiorespiratory depression and hypothermia; reduce the dose with other premedicants. Eyes stay open (protect the cornea); reflexes are kept; keep warm; redosing prolongs and worsens recovery. Overdose signs from 20 mg/kg; no antidote (doxapram may help).
  • Caution
    Not recommended in very young animals: the solvent contains benzyl alcohol.
Latin name
Tiletamine/Zolazepam
Georgian name
ტილეტამინი/ზოლაზეპამი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
2 of 2 forms
Products
Telazol, Zoletil
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Telazol 100 mg/ml, Solution

tiletamine 250 mg + zolazepam 250 mg, powder for solution for injection for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant IM immobilisation/brief anaesthesia or IV induction before inhalant maintenance in dogs
7.5/10
Good
vetman assessment

Telazol

tiletamine 250 mg + zolazepam 250 mg, powder for solution for injection for dogs and cats
Assessed clinical scopeDog · Label-concordant IM immobilisation/brief anaesthesia or IV induction before inhalant maintenance in dogs · IM,IV
Care settingFully equipped veterinary anaesthesia setting with pre-anaesthetic assessment, oxygen, airway and ventilation support, continuous physiologic monitoring, rescue analgesia and staffed recovery.
vetman score 7.5/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A well-supported exact US/Georgian product for canine IM immobilisation and IV induction; reliable utility is offset by cardiopulmonary monitoring needs and potentially prolonged or rough recovery.

Regulatory and scientific credibility8.5/10

Exact Telazol has current Georgian and FDA veterinary authorisations with NADA label and FOI support; exact EU/GB negatives are documented with Zoletil positive controls, so no sibling authorisation is transferred.

Clinical efficacy8.5/10

Rapid, reliable immobilisation and induction are supported by exact labels, FDA review for canine IV induction and direct physiologic/induction studies. The role is strongest for brief procedures or transition to inhalant maintenance, not prolonged stand-alone anaesthesia.

Safety and tolerability5.5/10

Respiratory depression, transient hypoxaemia/acidosis, sympathetic cardiovascular effects, salivation, emergence reactions and prolonged recovery are clinically important; canine zolazepam may clear before tiletamine and worsen recovery quality.

Clinical practicality7.5/10

A compact reconstituted 100 mg/ml solution supports IM immobilisation and titrated IV induction, but preparation, controlled access, exact slow IV titration, airway readiness and prolonged monitored recovery add burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only in a fully equipped anaesthesia setting. Pre-oxygenate when indicated; have a patent airway, oxygen, ventilation, suction, emergency drugs and trained continuous monitoring available before injection.
  • Immobility is not complete analgesia. Add procedure-appropriate multimodal analgesia for painful interventions and use an inhalant or other maintenance plan when duration or surgical stimulus exceeds the product’s brief role.
  • Respiratory depression, hypoxaemia, hypercapnia and apneustic breathing can occur, especially after IV or higher doses. Monitor SpO2 and ventilation, use capnography when possible, and be ready to intubate and ventilate.
  • Heart rate and blood pressure may rise through sympathetic stimulation, yet hypotension or arrhythmia can occur in compromised patients or combinations. Avoid assuming preserved blood pressure means adequate ventilation or perfusion.
  • Dogs may recover slowly or dysphorically because zolazepam is eliminated before tiletamine. Recover in a quiet, dark, padded area with continuous observation until protective reflexes, temperature and coordinated ambulation are adequate.
  • Avoid or apply a stringent benefit-risk assessment in severe cardiac, respiratory, renal, hepatic or pancreatic disease, shock, head trauma, raised intracranial pressure, seizure disorders or penetrating ocular injury.
  • Do not use during pregnancy or caesarean section unless an exact current label explicitly permits it and the neonatal risk is justified. Reproductive and very young-animal safety is limited.
  • Reconstitute only as the exact label directs and calculate in total combined mg/kg. Telazol uses 5 ml diluent; follow the current FDA label for asepsis, in-use storage and discard timing.
  • Titrate IV administration to effect and respect route-, indication- and species-specific maximums. Do not combine the IM and IV tables or redose automatically.
  • Review the entire premedication and anaesthetic plan. Alpha-2 agonists, opioids, phenothiazines, inhalants and other depressants can materially change cardiovascular, respiratory, analgesic and recovery effects; use only a deliberately balanced protocol.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20222022
  3. Zoletil/Telazol market audit2026
  4. AAHA anaesthesia guideline2020
  5. Tiletamine-zolazepam clinical review2026
  6. Telazol IV dog FOI2017
  7. Canine blood-gas trial2005
  8. Canine randomized induction trial2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant IM immobilisation and brief anaesthesia for defined diagnostic and surgical procedures in cats
7.0/10
Good
vetman assessment

Telazol

tiletamine 250 mg + zolazepam 250 mg, powder for solution for injection for dogs and cats
Assessed clinical scopeCat · Label-concordant IM immobilisation and brief anaesthesia for defined diagnostic and surgical procedures in cats · Intramuscular
Care settingFully equipped veterinary anaesthesia setting with pre-anaesthetic assessment, oxygen, airway and ventilation support, continuous physiologic monitoring, rescue analgesia and staffed recovery.
vetman score 7.0/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A useful exact IM feline anaesthetic for selected healthy cats and brief procedures, with narrower route flexibility and meaningful respiratory, pulmonary-oedema and recovery limitations.

Regulatory and scientific credibility8.5/10

Exact Telazol has current Georgian and FDA veterinary authorisations with NADA label and FOI support; exact EU/GB negatives are documented with Zoletil positive controls, so no sibling authorisation is transferred.

Clinical efficacy7.5/10

Exact labels and feline clinical studies support rapid immobilisation and short anaesthesia. Evidence is older and heterogeneous and does not justify treating dissociative immobility as complete analgesia for every painful procedure.

Safety and tolerability5.0/10

Respiratory depression or apneustic breathing, hypoxaemia, hypothermia, pulmonary oedema reports, salivation and prolonged recovery require close monitoring; organ disease and high-risk patients materially narrow the safety margin.

Clinical practicality7.0/10

Small-volume IM administration is useful when venous access is difficult, but cats have no labelled IV route, doses vary by procedure, and reconstitution, controlled access, airway readiness and prolonged monitored recovery add burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only in a fully equipped anaesthesia setting. Pre-oxygenate when indicated; have a patent airway, oxygen, ventilation, suction, emergency drugs and trained continuous monitoring available before injection.
  • Immobility is not complete analgesia. Add procedure-appropriate multimodal analgesia for painful interventions and use an inhalant or other maintenance plan when duration or surgical stimulus exceeds the product’s brief role.
  • Respiratory depression, hypoxaemia, hypercapnia and apneustic breathing can occur, especially after IV or higher doses. Monitor SpO2 and ventilation, use capnography when possible, and be ready to intubate and ventilate.
  • Heart rate and blood pressure may rise through sympathetic stimulation, yet hypotension or arrhythmia can occur in compromised patients or combinations. Avoid assuming preserved blood pressure means adequate ventilation or perfusion.
  • Cats may show prolonged recovery, hypothermia, salivation, vocalisation or excitation; pulmonary oedema has been reported. Monitor temperature, respiration and oxygenation through the full recovery period.
  • Avoid or apply a stringent benefit-risk assessment in severe cardiac, respiratory, renal, hepatic or pancreatic disease, shock, head trauma, raised intracranial pressure, seizure disorders or penetrating ocular injury.
  • Do not use during pregnancy or caesarean section unless an exact current label explicitly permits it and the neonatal risk is justified. Reproductive and very young-animal safety is limited.
  • Reconstitute only as the exact label directs and calculate in total combined mg/kg. Telazol uses 5 ml diluent; follow the current FDA label for asepsis, in-use storage and discard timing.
  • Telazol cats are labelled for IM use only. Do not transfer Zoletil’s feline IV regimen merely because the final concentration is the same.
  • Review the entire premedication and anaesthetic plan. Alpha-2 agonists, opioids, phenothiazines, inhalants and other depressants can materially change cardiovascular, respiratory, analgesic and recovery effects; use only a deliberately balanced protocol.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20222022
  3. Zoletil/Telazol market audit2026
  4. AAHA anaesthesia guideline2020
  5. Tiletamine-zolazepam clinical review2026
  6. Feline short-anaesthesia series1994
  7. Feline randomized premedication trial2014
  8. Feline cardiorespiratory crossover2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Tiletamine/Zolazepam100 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Intravenous
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: თელაზოლი®
Verified on: 22 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US Yes, veterinary
№ NADA 106-111
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Zoletil 100, Solution

tiletamine 50 mg/ml + zolazepam 50 mg/ml, lyophilisate and solvent for solution for injection for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant IM/IV immobilisation, brief anaesthesia or induction in dogs, with adjunct analgesia for painful procedures
7.6/10
Good
vetman assessment

Zoletil

100, tiletamine 50 mg/ml + zolazepam 50 mg/ml, lyophilisate and solvent for solution for injection for dogs and cats
Assessed clinical scopeDog · Label-concordant IM/IV immobilisation, brief anaesthesia or induction in dogs, with adjunct analgesia for painful procedures · IM,IV
Care settingFully equipped veterinary anaesthesia setting with pre-anaesthetic assessment, oxygen, airway and ventilation support, continuous physiologic monitoring, rescue analgesia and staffed recovery.
vetman score 7.6/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A well-documented, broadly authorised exact product for rapid dog immobilisation and short anaesthesia, useful when its recovery profile, respiratory risk and incomplete analgesic coverage are actively managed.

Regulatory and scientific credibility9.5/10

Exact Zoletil 100 has current Georgian, EU/EEA and GB veterinary authorisations, a current detailed VMD SPC and transparent exact composition; the US negative is exact-name-specific and has Telazol as a positive control.

Clinical efficacy8.0/10

Rapid, reliable immobilisation and induction are supported by exact labels, FDA review for canine IV induction and direct physiologic/induction studies. The role is strongest for brief procedures or transition to inhalant maintenance, not prolonged stand-alone anaesthesia.

Safety and tolerability5.5/10

Respiratory depression, transient hypoxaemia/acidosis, sympathetic cardiovascular effects, salivation, emergence reactions and prolonged recovery are clinically important; canine zolazepam may clear before tiletamine and worsen recovery quality.

Clinical practicality7.5/10

One reconstituted 100 mg/ml solution supports small-volume IM or titrated IV delivery in both species, but preparation, accurate indication-specific dosing, asepsis, refrigerated seven-day in-use storage and a fully monitored recovery add burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only in a fully equipped anaesthesia setting. Pre-oxygenate when indicated; have a patent airway, oxygen, ventilation, suction, emergency drugs and trained continuous monitoring available before injection.
  • Immobility is not complete analgesia. Add procedure-appropriate multimodal analgesia for painful interventions and use an inhalant or other maintenance plan when duration or surgical stimulus exceeds the product’s brief role.
  • Respiratory depression, hypoxaemia, hypercapnia and apneustic breathing can occur, especially after IV or higher doses. Monitor SpO2 and ventilation, use capnography when possible, and be ready to intubate and ventilate.
  • Heart rate and blood pressure may rise through sympathetic stimulation, yet hypotension or arrhythmia can occur in compromised patients or combinations. Avoid assuming preserved blood pressure means adequate ventilation or perfusion.
  • Dogs may recover slowly or dysphorically because zolazepam is eliminated before tiletamine. Recover in a quiet, dark, padded area with continuous observation until protective reflexes, temperature and coordinated ambulation are adequate.
  • Avoid or apply a stringent benefit-risk assessment in severe cardiac, respiratory, renal, hepatic or pancreatic disease, shock, head trauma, raised intracranial pressure, seizure disorders or penetrating ocular injury.
  • Do not use during pregnancy or caesarean section unless an exact current label explicitly permits it and the neonatal risk is justified. Reproductive and very young-animal safety is limited.
  • Reconstitute only as the exact label directs and calculate in total combined mg/kg. Zoletil 100 uses its supplied 5 ml solvent and the current VMD label allows seven days refrigerated after reconstitution.
  • Titrate IV administration to effect and respect route-, indication- and species-specific maximums. Do not combine the IM and IV tables or redose automatically.
  • Review the entire premedication and anaesthetic plan. Alpha-2 agonists, opioids, phenothiazines, inhalants and other depressants can materially change cardiovascular, respiratory, analgesic and recovery effects; use only a deliberately balanced protocol.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20222022
  3. Zoletil/Telazol market audit2026
  4. AAHA anaesthesia guideline2020
  5. Tiletamine-zolazepam clinical review2026
  6. Telazol IV dog FOI2017
  7. Canine blood-gas trial2005
  8. Canine randomized induction trial2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant IM/IV immobilisation or brief anaesthesia in cats, with adjunct analgesia for painful procedures
7.4/10
Good
vetman assessment

Zoletil

100, tiletamine 50 mg/ml + zolazepam 50 mg/ml, lyophilisate and solvent for solution for injection for dogs and cats
Assessed clinical scopeCat · Label-concordant IM/IV immobilisation or brief anaesthesia in cats, with adjunct analgesia for painful procedures · IM,IV
Care settingFully equipped veterinary anaesthesia setting with pre-anaesthetic assessment, oxygen, airway and ventilation support, continuous physiologic monitoring, rescue analgesia and staffed recovery.
vetman score 7.4/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A well-documented, broadly authorised exact product with both IM and IV feline options, but it remains a monitored dissociative anaesthetic—not a substitute for airway support, balanced analgesia or careful recovery.

Regulatory and scientific credibility9.5/10

Exact Zoletil 100 has current Georgian, EU/EEA and GB veterinary authorisations, a current detailed VMD SPC and transparent exact composition; the US negative is exact-name-specific and has Telazol as a positive control.

Clinical efficacy7.5/10

Exact labels and feline clinical studies support rapid immobilisation and short anaesthesia. Evidence is older and heterogeneous and does not justify treating dissociative immobility as complete analgesia for every painful procedure.

Safety and tolerability5.0/10

Respiratory depression or apneustic breathing, hypoxaemia, hypothermia, pulmonary oedema reports, salivation and prolonged recovery require close monitoring; organ disease and high-risk patients materially narrow the safety margin.

Clinical practicality7.5/10

One reconstituted 100 mg/ml solution supports small-volume IM or titrated IV delivery in both species, but preparation, accurate indication-specific dosing, asepsis, refrigerated seven-day in-use storage and a fully monitored recovery add burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only in a fully equipped anaesthesia setting. Pre-oxygenate when indicated; have a patent airway, oxygen, ventilation, suction, emergency drugs and trained continuous monitoring available before injection.
  • Immobility is not complete analgesia. Add procedure-appropriate multimodal analgesia for painful interventions and use an inhalant or other maintenance plan when duration or surgical stimulus exceeds the product’s brief role.
  • Respiratory depression, hypoxaemia, hypercapnia and apneustic breathing can occur, especially after IV or higher doses. Monitor SpO2 and ventilation, use capnography when possible, and be ready to intubate and ventilate.
  • Heart rate and blood pressure may rise through sympathetic stimulation, yet hypotension or arrhythmia can occur in compromised patients or combinations. Avoid assuming preserved blood pressure means adequate ventilation or perfusion.
  • Cats may show prolonged recovery, hypothermia, salivation, vocalisation or excitation; pulmonary oedema has been reported. Monitor temperature, respiration and oxygenation through the full recovery period.
  • Avoid or apply a stringent benefit-risk assessment in severe cardiac, respiratory, renal, hepatic or pancreatic disease, shock, head trauma, raised intracranial pressure, seizure disorders or penetrating ocular injury.
  • Do not use during pregnancy or caesarean section unless an exact current label explicitly permits it and the neonatal risk is justified. Reproductive and very young-animal safety is limited.
  • Reconstitute only as the exact label directs and calculate in total combined mg/kg. Zoletil 100 uses its supplied 5 ml solvent and the current VMD label allows seven days refrigerated after reconstitution.
  • Titrate IV administration to effect and respect route-, indication- and species-specific maximums. Do not combine the IM and IV tables or redose automatically.
  • Review the entire premedication and anaesthetic plan. Alpha-2 agonists, opioids, phenothiazines, inhalants and other depressants can materially change cardiovascular, respiratory, analgesic and recovery effects; use only a deliberately balanced protocol.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20222022
  3. Zoletil/Telazol market audit2026
  4. AAHA anaesthesia guideline2020
  5. Tiletamine-zolazepam clinical review2026
  6. Feline short-anaesthesia series1994
  7. Feline randomized premedication trial2014
  8. Feline cardiorespiratory crossover2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Tiletamine/Zolazepam100 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Intravenous
Manufacturer
Virbac · France
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ზოლეტილი® 100
Verified on: 22 Oct 2026
 EU Yes, veterinary
Verified on: 22 Oct 2026
 UK Yes, veterinary
№ Vm 05653/3048
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 22 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗